A Phase 2 Study Comparing Chemotherapy in Combination With OGX-427 or Placebo in Patients With Bladder Cancer



Status:Completed
Conditions:Prostate Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:18 - Any
Updated:4/21/2016
Start Date:October 2011
End Date:November 2014

Use our guide to learn which trials are right for you!

A Randomized, Double-blind Phase 2 Study Comparing Gemcitabine and Cisplatin in Combination With OGX-427 or Placebo in Patients With Advanced Transitional Cell Carcinoma

This study evaluates the safety and efficacy of standard chemotherapy in combination with
the investigational drug OGX-427 in patients with advanced bladder cancer.

The incidence of bladder cancer in 2010 in the US and Canada combined is estimated to be
77,680, with 16,520 deaths and in Europe in 2008 was 110,500 with 38,200 deaths. The most
common histological type is transitional cell cancer (TCC). Most cases (70%) present with
superficial or non-invasive disease which, in general, has a good prognosis. However, at
diagnosis, 20% of patients will have advanced disease (muscular invasion) and 5% will
present with metastatic disease. In addition, 50-70% of superficial tumors will recur and a
significant proportion will evolve to muscular involvement within 5 years. Radical
cystectomy is the treatment of choice for patients with operable invasive disease. Patients
who present with locally inoperable disease due to local extension into organs other than
the bladder or involvement of regional lymph nodes do not have this option, and, despite
radical cystectomy, 50% of patients will recur either regionally (~30%) or systemically
(~70%) following cystectomy. Following recurrence, few patients can be cured.

Before the advent of chemotherapy, survival of patients with metastatic TCC was <6 months.
Today, TCC is felt to be a chemotherapy sensitive disease, and systemic chemotherapy is the
treatment of choice for patients with inoperable, locally advanced, or metastatic disease.

This study evaluates the safety and efficacy of the standard chemotherapy (gemcitabine and
cisplatin) in combination with OGX-427 at two dose levels (600 mg and 1000 mg) or placebo in
patients with advanced TCC who have not previously received chemotherapy for metastatic
disease and are not candidates for potential curative surgery or radiotherapy.

Inclusion Criteria:

1. Age ≥ 18 years at the time of consent

2. Histologically documented metastatic or locally inoperable advanced TCC of the
urinary tract (bladder, urethra, ureter and renal pelvis) (T4b, N2, N3 or M1 disease)
NOTE: Certain mixed histologies that are predominately (≥ 50%) TCC are eligible:
squamous, adenocarcinoma, and undifferentiated. Mixed undifferentiated histology
requires IHC consistent with a TCC origin. Mixed small-cell histologies are excluded.

3. Measurable disease defined as at least one target lesion that has not been irradiated
and can be accurately measured in at least one dimension by RECIST 1.1 criteria

4. No prior systemic chemotherapy with the following exceptions:

- Prior use of radiosensitizing single agent therapy is allowed

- Prior neoadjuvant and adjuvant chemotherapy may be allowed

5. Minimum of 21 days since prior major surgery or radiation therapy

6. Karnofsky performance status ≥70%

7. Required laboratory values at baseline:

- ANC ≥ 1.5x109 cells/L

- platelet count ≥ 125 x 109/L

- Calculated creatinine clearance ≥60 mL/minute

- bilirubin ≤ 1.5 x ULN (≤ 2.5 x ULN if secondary to Gilbert's disease)

- AST and ALT ≤ 3.0 x ULN

8. If of child-bearing potential, willing to use contraceptives

9. Willing to give written informed consent

Exclusion Criteria:

1. A candidate for potential curative surgery or radiotherapy

2. Intravesical therapy within the last 3 months

3. Documented brain metastasis or carcinomatous meningitis, treated or untreated. NOTE:
Brain imaging is not required unless the patient has symptoms or physical signs of
CNS disease.

4. Peripheral neuropathy ≥Grade 2

5. Known serious hypersensitivity to gemcitabine, cisplatin or carboplatin

6. Current serious, uncontrolled medical condition such as congestive heart failure,
angina, hypertension, arrhythmia, diabetes mellitus, infection, etc. or any condition
such as a psychiatric illness which in the opinion of the investigator would make the
patient unacceptable for the protocol

7. Cerebrovascular accident, myocardial infarction or pulmonary embolus within 6 months
of randomization

8. Active second malignancy (except non-melanomatous skin cancer): active secondary
malignancy is defined as a current need for cancer therapy or a high possibility
(>30%) of recurrence during the study

9. Pregnant or nursing (must have a negative serum or urine pregnancy test within 72
hours prior to randomization)

10. Participating in a concurrent clinical trial of an experimental drug, vaccine or
device. Participation in an observational study is allowed.
We found this trial at
15
sites
?
mi
from
Omaha, NE
Click here to add this to my saved trials
Los Angeles, California 90095
310-825-4321
University of California at Los Angeles The University of California, Los Angeles (UCLA) is an...
?
mi
from
Los Angeles, CA
Click here to add this to my saved trials
8700 Beverly Blvd # 8211
Los Angeles, California 90048
(1-800-233-2771)
Cedars Sinai Med Ctr Cedars-Sinai is known for providing the highest quality patient care. Our...
?
mi
from
Los Angeles, CA
Click here to add this to my saved trials
825 Eastlake Ave E
Seattle, Washington 98109
(206) 288-7222
Seattle Cancer Care Alliance Seattle Cancer Care Alliance (SCCA) is a cancer treatment center that...
?
mi
from
Seattle, WA
Click here to add this to my saved trials
?
mi
from
Bronx, NY
Click here to add this to my saved trials
Calgary, Alberta
?
mi
from
Calgary,
Click here to add this to my saved trials
Dallas, Texas 75246
?
mi
from
Dallas, TX
Click here to add this to my saved trials
Detroit, Michigan 48201
?
mi
from
Detroit, MI
Click here to add this to my saved trials
1500 East Duarte Road
Duarte, California 91010
626-256-HOPE (4673)
City of Hope National Medical Center City of Hope is dedicated to making a difference...
?
mi
from
Duarte, CA
Click here to add this to my saved trials
450 Lakeville Rd
Lake Success, New York 11040
(516) 734-8900
Monter Cancer Center The Monter Cancer Center is a unique facility dedicated to providing state-of-the-art...
?
mi
from
Lake Success, NY
Click here to add this to my saved trials
1441 Eastlake Ave
Los Angeles, California 90033
(323) 865-3000
U.S.C./Norris Comprehensive Cancer Center The USC Norris Comprehensive Cancer Center, located in Los Angeles, is...
?
mi
from
Los Angeles, CA
Click here to add this to my saved trials
New Haven, Connecticut 6520
(203) 432-4771
Yale University Yale's roots can be traced back to the 1640s, when colonial clergymen led...
?
mi
from
New Haven, CT
Click here to add this to my saved trials
630 W 168th St
New York, New York
212-305-2862
Columbia University Medical Center Situated on a 20-acre campus in Northern Manhattan and accounting for...
?
mi
from
New York, NY
Click here to add this to my saved trials
Sacramento, California 95816
?
mi
from
Sacramento, CA
Click here to add this to my saved trials
?
mi
from
St. Louis, MO
Click here to add this to my saved trials